Coinspeaker GILD Stock Lost 4%, Gilead Sciences Disputes Report on Poor Results of Remdesivir TrialWHO accidentally posted a draft summary of remdesivir trial studies. As soon as the organization realized the mistake, it deleted the post. But Gilead (GILD) stock plunged.GILD Stock Lost 4%, Gilead Sciences Disputes Report on Poor Results of Remdesivir Trial